ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
67,114.74
-1.19%
S&P 500
5,267.84
-0.74%
Dow Jones
39,065.26
-1.53%
US Dollar vs Yen
157.0655
0.06%
Brent Oil
81.13
-0.22%
Registration Strip Icon for default 登録して無料でリアルタイムの株価、インタラクティブチャート、ライブオプションフローなどを入手してください。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Beam Therapeutics Inc (BEAM)

  7. Beam Therapeutics Inc (BEAM) ニュース

BEAM

Beam Therapeutics (BEAM)

Beam Therapeutics Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:BEAM
日付受信時刻ニュースソース見出しコード企業名
2024/05/1505 : 00GlobeNewswire Inc.Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid CongressNASDAQ:BEAMBeam Therapeutics Inc
2024/05/0819 : 30GlobeNewswire Inc.Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare ConferenceNASDAQ:BEAMBeam Therapeutics Inc
2024/05/0720 : 19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BEAMBeam Therapeutics Inc
2024/05/0720 : 09Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
2024/05/0719 : 30GlobeNewswire Inc.Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial ResultsNASDAQ:BEAMBeam Therapeutics Inc
2024/03/2619 : 30GlobeNewswire Inc.Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)NASDAQ:BEAMBeam Therapeutics Inc
2024/02/2820 : 30GlobeNewswire Inc.Beam Therapeutics to Participate in Upcoming March 2024 Investor ConferencesNASDAQ:BEAMBeam Therapeutics Inc
2024/02/2721 : 40Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:BEAMBeam Therapeutics Inc
2024/02/2721 : 22Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:BEAMBeam Therapeutics Inc
2024/02/2720 : 43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
2024/02/2720 : 30GlobeNewswire Inc.Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated MilestonesNASDAQ:BEAMBeam Therapeutics Inc
2024/02/0520 : 30GlobeNewswire Inc.Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:BEAMBeam Therapeutics Inc
2024/02/0306 : 05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
2024/02/0306 : 05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
2024/02/0306 : 05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
2024/02/0306 : 05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
2024/02/0306 : 05Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
2024/02/0106 : 47Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BEAMBeam Therapeutics Inc
2024/01/0820 : 55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
2024/01/0820 : 30GlobeNewswire Inc.Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated MilestonesNASDAQ:BEAMBeam Therapeutics Inc
2024/01/0606 : 30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
2024/01/0220 : 30GlobeNewswire Inc.Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:BEAMBeam Therapeutics Inc
2023/12/1506 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
2023/12/1420 : 30GlobeNewswire Inc.Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of DirectorsNASDAQ:BEAMBeam Therapeutics Inc
2023/11/2106 : 20Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BEAMBeam Therapeutics Inc
2023/11/0821 : 30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BEAMBeam Therapeutics Inc
2023/11/0821 : 00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
2023/11/0820 : 30GlobeNewswire Inc.Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial ResultsNASDAQ:BEAMBeam Therapeutics Inc
2023/11/0820 : 30GlobeNewswire Inc.Beam Therapeutics to Participate in 2023 Jefferies London Healthcare ConferenceNASDAQ:BEAMBeam Therapeutics Inc
2023/11/0205 : 30Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:BEAM

最近閲覧した銘柄

NASDAQ
TWCTU
TWC Tech Holdings II
BIT
UC4YA8
Unicredit Bank
BIT
F09574
Vontobel Financial Produ...
COIN
GALEONUSD
Galeon
NYSE
APX
GEMN
GALUSD
Gala
TSXV
IRI
IEMR Resources
TG
HNR1
Hannover Ruck
LSE
AN66
Citi Fun 29
NASDAQ
NBSE
NeuBase Therapeutics
AMEX
PSMD
Pacer Swan SOS Moderate ...
LSE
0FXT
Small Cap Danmark A/s
NASDAQI
FCVT
First Trust SSI Strategi...
FX
USDAUD
US Dollar vs AUD
BIT
UC8T32
Unicredit Bank
COIN
DBIXEUR
Delayed Upgrade Clock
ADVFN Logo

日本
会社情報
ビジネス
人気
アプリを入手

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2024 ADVFN PLC - 全著作権所有